As of 2026-04-05, the EV/EBITDA ratio of Pulmonx Corp (LUNG) is -0.46. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LUNG's latest enterprise value is 23.52 mil USD. LUNG's TTM EBITDA according to its financial statements is -50.62 mil USD. Dividing these 2 quantities gives us the above LUNG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.2x - 13.6x | 13.5x |
| Forward P/E multiples | 9.9x - 11.9x | 10.3x |
| Fair Price | (12.67) - (13.44) | (13.49) |
| Upside | -1052.8% - -1110.5% | -1114.1% |
| Date | EV/EBITDA |
| 2026-04-02 | -0.46 |
| 2026-04-01 | -0.42 |
| 2026-03-31 | -0.43 |
| 2026-03-30 | -0.34 |
| 2026-03-27 | -0.33 |
| 2026-03-26 | -0.39 |
| 2026-03-25 | -0.44 |
| 2026-03-24 | -0.45 |
| 2026-03-23 | -0.51 |
| 2026-03-20 | -0.49 |
| 2026-03-19 | -0.51 |
| 2026-03-18 | -0.59 |
| 2026-03-17 | -0.71 |
| 2026-03-16 | -0.70 |
| 2026-03-13 | -0.76 |
| 2026-03-12 | -0.84 |
| 2026-03-11 | -0.85 |
| 2026-03-10 | -0.84 |
| 2026-03-09 | -0.87 |
| 2026-03-06 | -1.04 |
| 2026-03-05 | -0.70 |
| 2026-03-04 | -0.56 |
| 2026-03-03 | -0.63 |
| 2026-03-02 | -0.63 |
| 2026-02-27 | -0.67 |
| 2026-02-26 | -0.72 |
| 2026-02-25 | -0.72 |
| 2026-02-24 | -0.61 |
| 2026-02-23 | -0.59 |
| 2026-02-20 | -0.61 |
| 2026-02-19 | -0.54 |
| 2026-02-18 | -0.54 |
| 2026-02-17 | -0.60 |
| 2026-02-13 | -0.58 |
| 2026-02-12 | -0.54 |
| 2026-02-11 | -0.56 |
| 2026-02-10 | -0.56 |
| 2026-02-09 | -0.64 |
| 2026-02-06 | -0.61 |
| 2026-02-05 | -0.56 |
| 2026-02-04 | -0.61 |
| 2026-02-03 | -0.65 |
| 2026-02-02 | -0.72 |
| 2026-01-30 | -0.72 |
| 2026-01-29 | -0.79 |
| 2026-01-28 | -0.82 |
| 2026-01-27 | -0.82 |
| 2026-01-26 | -0.85 |
| 2026-01-23 | -0.90 |
| 2026-01-22 | -0.95 |